Genesis R&D Awaits Japan Investor Infusion To Resume Operations
This article was originally published in PharmAsia News
Executive Summary
Genesis Research and Development, New Zealand's first biotech listed on stock markets, says it will have to suspend operations as it awaits necessary cash investments